PMID- 33743606
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20211214
IS  - 1471-2172 (Electronic)
IS  - 1471-2172 (Linking)
VI  - 22
IP  - 1
DP  - 2021 Mar 21
TI  - A putative exosporium lipoprotein GBAA0190 of Bacillus anthracis as a potential 
      anthrax vaccine candidate.
PG  - 20
LID - 10.1186/s12865-021-00414-y [doi]
LID - 20
AB  - BACKGROUND: Bacillus ancthracis causes cutaneous, pulmonary, or gastrointestinal 
      forms of anthrax. B. anthracis is a pathogenic bacterium that is potentially to 
      be used in bioterrorism because it can be produced in the form of spores. 
      Currently, protective antigen (PA)-based vaccines are being used for the 
      prevention of anthrax, but it is necessary to develop more safe and effective 
      vaccines due to their prolonged immunization schedules and adverse reactions. 
      METHODS: We selected the lipoprotein GBAA0190, a potent inducer of host immune 
      response, present in anthrax spores as a novel potential vaccine candidate. Then, 
      we evaluated its immune-stimulating activity in the bone marrow-derived 
      macrophages (BMDMs) using enzyme-linked immunosorbent assay (ELISA) and Western 
      blot analysis. Protective efficacy of GBAA0190 was evaluated in the guinea pig 
      (GP) model. RESULTS: The recombinant GBAA0190 (r0190) protein induced the 
      expression of various inflammatory cytokines including tumor necrosis factor-alpha 
      (TNF-alpha), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and 
      macrophage inflammatory protein-1alpha (MIP-1alpha) in the BMDMs. These immune responses 
      were mediated through toll-like receptor 1/2 via activation of mitogen-activated 
      protein (MAP) kinase and Nuclear factor-kappaB (NF-kappaB) pathways. We demonstrated that 
      not only immunization of r0190 alone, but also combined immunization with r0190 
      and recombinant PA showed significant protective efficacy against B. anthracis 
      spore challenges in the GP model. CONCLUSIONS: Our results suggest that r0190 may 
      be a potential target for anthrax vaccine.
FAU - Jeon, Jun Ho
AU  - Jeon JH
AD  - Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, 
      Korea Disease Control and Prevention Agency, Cheongju, 28159, Republic of Korea.
FAU - Kim, Yeon Hee
AU  - Kim YH
AD  - Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, 
      Korea Disease Control and Prevention Agency, Cheongju, 28159, Republic of Korea.
FAU - Kim, Kyung Ae
AU  - Kim KA
AD  - Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, 
      Korea Disease Control and Prevention Agency, Cheongju, 28159, Republic of Korea.
FAU - Kim, Yu-Ri
AU  - Kim YR
AD  - Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, 
      Korea Disease Control and Prevention Agency, Cheongju, 28159, Republic of Korea.
FAU - Woo, Sun-Je
AU  - Woo SJ
AD  - Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, 
      Korea Disease Control and Prevention Agency, Cheongju, 28159, Republic of Korea.
FAU - Choi, Ye Jin
AU  - Choi YJ
AD  - Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, 
      Korea Disease Control and Prevention Agency, Cheongju, 28159, Republic of Korea.
FAU - Rhie, Gi-Eun
AU  - Rhie GE
AD  - Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, 
      Korea Disease Control and Prevention Agency, Cheongju, 28159, Republic of Korea. 
      gerhie@korea.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210321
PL  - England
TA  - BMC Immunol
JT  - BMC immunology
JID - 100966980
RN  - 0 (Anthrax Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (Lipoproteins)
RN  - 0 (NF-kappa B)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Toll-Like Receptors)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Animals
MH  - Anthrax/*prevention & control
MH  - Anthrax Vaccines/administration & dosage/genetics/*immunology
MH  - Bacillus anthracis/*immunology
MH  - Cytokines/metabolism
MH  - Guinea Pigs
MH  - Immunization
MH  - Lipoproteins/administration & dosage/genetics/*immunology
MH  - Macrophages/immunology/metabolism
MH  - Mice
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - NF-kappa B/metabolism
MH  - Recombinant Proteins/administration & dosage/genetics/immunology
MH  - Signal Transduction
MH  - Spores, Bacterial/immunology
MH  - Toll-Like Receptors/metabolism
PMC - PMC7981958
OTO - NOTNLM
OT  - Anthrax
OT  - Bacillus anthracis
OT  - Exosporium lipoprotein
OT  - Vaccine
COIS- The authors declare that they have no competing interests.
EDAT- 2021/03/22 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/03/21
CRDT- 2021/03/21 20:26
PHST- 2020/11/20 00:00 [received]
PHST- 2021/03/10 00:00 [accepted]
PHST- 2021/03/21 20:26 [entrez]
PHST- 2021/03/22 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/03/21 00:00 [pmc-release]
AID - 10.1186/s12865-021-00414-y [pii]
AID - 414 [pii]
AID - 10.1186/s12865-021-00414-y [doi]
PST - epublish
SO  - BMC Immunol. 2021 Mar 21;22(1):20. doi: 10.1186/s12865-021-00414-y.